Edition:
United States

Inovio Pharmaceuticals Inc (INO.OQ)

INO.OQ on NASDAQ Stock Exchange Global Select Market

4.54USD
21 Aug 2018
Change (% chg)

$0.15 (+3.42%)
Prev Close
$4.39
Open
$4.37
Day's High
$4.54
Day's Low
$4.37
Volume
101,802
Avg. Vol
175,775
52-wk High
$7.00
52-wk Low
$3.64

Select another date:

Mon, May 21 2018

BRIEF-Inovio Opens Trial To Test Its VGX-3100 Drug In HPV Patients

* INOVIO OPENS PHASE 2 TRIAL FOR VGX-3100 IN THIRD INDICATION TO TREAT HPV – THE NO. 1 SEXUALLY TRANSMITTED DISEASE

BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial

* INOVIO HIV VACCINE, WHICH GENERATED NEAR 100% IMMUNE RESPONSES, SUSTAINED DURABLE MEMORY RESPONSES MEASURED ONE YEAR AFTER THE START OF CLINICAL TRIAL Source text for Eikon: Further company coverage:

BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36

* INOVIO PHARMACEUTICALS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36

* INOVIO PHARMACEUTICALS SAYS FOR THREE MONTHS ENDED MARCH 31, 2018, NET LOSS PER SHARE WAS $0.36 - SEC FILING

BRIEF-Inovio Awarded Up To $56 Million From Cepi To Advance Dna Vaccines Against Lassa Fever And Mers

* INOVIO AWARDED UP TO $56 MILLION FROM CEPI TO ADVANCE DNA VACCINES AGAINST LASSA FEVER AND MERS

BRIEF-Inovio Closes License And Collaboration Agreement With ApolloBio To Develop And Commercialize VGX-3100 In Greater China

* INOVIO CLOSES LICENSE AND COLLABORATION AGREEMENT WITH APOLLOBIO TO DEVELOP AND COMMERCIALIZE VGX-3100 IN GREATER CHINA

BRIEF-Inovio Pharmaceuticals Reports Qtrly ‍Net Loss Attributable To Stockholders Of $0.24 Per Basic Share​

* INOVIO PHARMACEUTICALS REPORTS 2017 FOURTH QUARTER AND YEAR END FINANCIAL RESULTS

BRIEF-Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key In Treating Chronic Hepatitis B Infection

* INOVIO'S DNA IMMUNOTHERAPY DEMONSTRATES IMMUNE RESPONSE RESULTS KEY IN TREATING CHRONIC HEPATITIS B INFECTION Source text for Eikon: Further company coverage:

Select another date: